Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics develops allogeneic chimeric antigen receptor T cell, or AlloCAR T, product candidates for cancer and autoimmune disease. The clinical-stage biotechnology company focuses on off-the-shelf CAR T approaches, including cemacabtagene ansegedleucel, or cema-cel, in large B-cell lymphoma and ALLO-329, a dual CD19/CD70 CAR T candidate for autoimmune diseases.
Recurring news covers clinical and regulatory updates for Allogene's studies, scientific presentations and publications, platform technologies such as Dagger®, and data related to MRD-guided treatment approaches. Company updates also include quarterly financial results, business updates, shareholder matters, and common stock financing activity tied to research, development, clinical trials, and corporate operations.
Natera highlighted Allogene Therapeutics' interim futility analysis from the ALPHA3 trial (ALLO) on April 13, 2026. The analysis reported 58.3% MRD clearance with cema-cel and a median 97.7% ctDNA decrease at Day 45 versus a 26.6% median increase in observation.
The trial uses Natera's CLARITY MRD assay to randomize MRD-positive LBCL patients to cema-cel or observation; results are interim and final clinical outcomes remain pending.
Allogene (Nasdaq: ALLO) reported interim futility results from the randomized Phase 2 ALPHA3 trial in first-line consolidation large B-cell lymphoma showing 58.3% MRD negativity with cemacabtagene ansegedleucel (cema-cel) versus 16.7% on observation (a 41.6% absolute difference) at Day 45.
Plasma ctDNA fell a median 97.7% in the cema-cel arm vs a 26.6% median increase in observation. No CRS, ICANS, GvHD, or treatment-related serious adverse events were reported; 10 of 12 cema-cel patients were managed outpatient. Enrollment of ~220 patients expected to complete by end-2027; interim EFS analysis anticipated mid-2027, primary EFS mid-2028.
Allogene (Nasdaq: ALLO) will present interim futility analysis data from its pivotal, randomized Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026.
The company will host a live conference call and webcast at 5:30 a.m. PT / 8:30 a.m. ET; the webcast will be available under the Investors / News and Events section at the company website.
Allogene (Nasdaq: ALLO) reported Q4 and full-year 2025 results and provided program updates. Key points: $258.3 million in cash and investments as of Dec 31, 2025; cash runway extended into Q1 2028. Pivotal ALPHA3 interim futility analysis planned for April 2026; RESOLUTION data expected June 2026.
2025 net loss was $190.9 million; guidance for 2026 operating cash expense is ~$150 million and GAAP operating expenses ~$210 million.
Allogene Therapeutics (NASDAQ: ALLO) will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after market close. A live audio webcast and conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.
According to the company, the listen-only webcast will be available on its investor website, with a replay accessible for about 30 days. Registered participants who request to speak will receive a personal PIN.
Allogene Therapeutics (Nasdaq: ALLO) will participate in two investor conferences in Q1 2026: Citi's 2026 Virtual Oncology Leadership Summit on Feb 18, 2026 at 9:15 AM PT / 12:15 PM ET and TD Cowen 46th Annual Health Care Conference on Mar 3, 2026 at 8:50 AM PT / 11:50 AM ET. Any available webcasts and replays will be posted on the company website under Investors > News and Events.
Allogene Therapeutics (Nasdaq: ALLO) positioned 2026 as a program-defining year with multiple H1 clinical readouts aimed at validating off-the-shelf AlloCAR T across oncology and autoimmune disease. Key near-term milestones include an early Q2 2026 interim futility analysis of MRD clearance from the pivotal Phase 2 ALPHA3 trial of cema-cel in 1L consolidation LBCL and initial proof-of-concept data for ALLO-329 (dual CD19/CD70 with Dagger®) by end of 1H 2026. The platform targets manufacturing scale of ~30,000–60,000+ doses annually and a COGS profile of <$10K–20K per dose. ALLO-316 showed a 31% confirmed ORR in high CD70 RCC patients. Cash runway is expected into 2H 2027 (excludes BD activity).
Allogene (Nasdaq: ALLO) announced a favorable arbitration ruling that reconfirms its full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the United States, all EU member states, and the United Kingdom and clears a path to obtain full global commercialization rights from Servier.
The tribunal rejected Cellectis’s claims, found milestone payments tied to the pivotal trial are due only upon FDA acceptance of a BLA, and limited license termination to the UCART19 V1 product (ALLO-501). Allogene expects a meaningful catalyst with a 1H 2026 interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cema-cel in 1L consolidation for large B-cell lymphoma (LBCL).
Allogene Therapeutics (Nasdaq: ALLO) will participate in three investor conferences in November and December 2025. Scheduled events:
- TD Cowen Immunology & Inflammation Virtual Summit — Wednesday, November 12 at 1:30 PM PT / 4:30 PM ET.
- Jefferies Global Healthcare Conference, London — Tuesday, November 18 at 2:00 AM PT / 5:00 AM ET / 10:00 AM GMT.
- Piper Sandler 37th Annual Healthcare Conference — Tuesday, December 2 at 9:00 AM PT / 12:00 PM ET.
Allogene Therapeutics (Nasdaq: ALLO) reported Q3 2025 results and provided program updates on November 6, 2025. Key financials: $277.1M in cash, cash equivalents and investments as of Sept 30, 2025, with cash runway projected into 2H 2027 and an expected 2025 cash decline of ~$150M. Q3 operating metrics: R&D $31.2M, G&A $13.7M, and net loss $41.4M ( $0.19/share). GAAP operating expenses guidance for 2025 is ~$230M including ~$45M stock-based comp.
Clinical milestones: pivotal Phase 2 ALPHA3 futility analysis (MRD conversion) on track for 1H 2026; ALLO-329 RESOLUTION PoC and biomarker update planned for 1H 2026; ALLO-316 showed durable responses in RCC and TRAVERSE completed Phase 1b enrollment.